首页 > 最新文献

Journal of Clinical and Experimental Hepatology最新文献

英文 中文
Use of Bacterial DNA Concentration in Ascites as a Marker for Spontaneous Bacterial Peritonitis 利用腹水中的细菌 DNA 浓度作为自发性细菌性腹膜炎的标志物
IF 3 Q2 Medicine Pub Date : 2024-05-01 DOI: 10.1016/j.jceh.2024.101434
Niklas F. Aehling , Arno Hagenunger , Sandra Krohn , Katharina Zeller , Kathrin Jäger , Adam Herber , Cornelius Engelmann , Thomas Berg

Background and aims

Spontaneous bacterial peritonitis (SBP) is a common and serious complication in patients with decompensated cirrhosis. Precise quantification of bacterial DNA (bactDNA) and the related inflammatory response might add further information on the course of disease. The aim of the study was to evaluate the association between bactDNA, cytokine levels and clinical outcome.

Methods

Ascites and serum samples of 98 patients with decompensated liver cirrhosis (42 with SBP and 56 without SBP) as well as serum samples of 21 healthy controls were collected. BactDNA in ascites and serum was detected and quantified by 16S rRNA PCR. Concentrations of IL-1β, TNF-α, IL-6, IL-8 and IL-10 were measured by a LEGENDplexTM multi-analyte flow assay. Clinical data were collected and analyzed retrospectively.

Results

BactDNA was detected more frequently in ascites of patients with SBP (n = 24/42; 57.1%) than in ascites of patients without SBP (n = 5/56; 8.9%; P < 0.001). Additionally, IL-6 levels in both ascites and serum were significantly higher in patients with SBP (ascites P < 0.001, serum P = 0.036). The quantity of bactDNA in ascites was strongly correlated with polymorphonuclear neutrophil count in ascites (r = 0.755; P < 0.001) as well as ascites IL-6 levels (r = 0.399; P < 0.001). Receiver operating characteristic (ROC) curve analysis to diagnose SBP provided an AUC of 0.764 (95% CI: 0.661–0.867) for serum IL-6 levels, an AUC of 0.810 (95% CI: 0.714–0.905) for ascites IL-6 levels, and an AUC of 0.755 (95% CI: 0.651–0.858) for bactDNA levels in ascites.

Conclusions

The correlation between the amount of bactDNA and IL-6 confirms the pathophysiological relevance of bactDNA and IL-6 as potential biomarkers for the diagnosis of SBP.

背景和目的自发性细菌性腹膜炎(SBP)是失代偿期肝硬化患者常见的严重并发症。对细菌 DNA(bactDNA)和相关炎症反应的精确定量可进一步了解病程。研究旨在评估 bactDNA、细胞因子水平和临床预后之间的关联。方法收集了 98 例失代偿期肝硬化患者(42 例伴有 SBP,56 例无 SBP)的腹水和血清样本,以及 21 例健康对照者的血清样本。通过 16S rRNA PCR 检测腹水和血清中的 BactDNA 并进行定量。IL-1β、TNF-α、IL-6、IL-8 和 IL-10 的浓度通过 LEGENDplexTM 多分析流式分析仪进行测定。结果在 SBP 患者腹水中检测到的 BactDNA(n = 24/42;57.1%)多于在非 SBP 患者腹水中检测到的 BactDNA(n = 5/56;8.9%;P <;0.001)。此外,SBP 患者腹水和血清中的 IL-6 水平均显著升高(腹水 P < 0.001,血清 P = 0.036)。腹水中的 bactDNA 数量与腹水中的多形核中性粒细胞计数(r = 0.755; P <0.001)和腹水 IL-6 水平(r = 0.399; P <0.001)密切相关。诊断 SBP 的接收者操作特征(ROC)曲线分析显示,血清 IL-6 水平的 AUC 为 0.764(95% CI:0.661-0.867),腹水 IL-6 水平的 AUC 为 0.810(95% CI:0.714-0.905),腹水 IL-6 水平的 AUC 为 0.结论 bactDNA 和 IL-6 的含量之间的相关性证实了 bactDNA 和 IL-6 作为诊断 SBP 的潜在生物标记物的病理生理学相关性。
{"title":"Use of Bacterial DNA Concentration in Ascites as a Marker for Spontaneous Bacterial Peritonitis","authors":"Niklas F. Aehling ,&nbsp;Arno Hagenunger ,&nbsp;Sandra Krohn ,&nbsp;Katharina Zeller ,&nbsp;Kathrin Jäger ,&nbsp;Adam Herber ,&nbsp;Cornelius Engelmann ,&nbsp;Thomas Berg","doi":"10.1016/j.jceh.2024.101434","DOIUrl":"10.1016/j.jceh.2024.101434","url":null,"abstract":"<div><h3>Background and aims</h3><p>Spontaneous bacterial peritonitis (SBP) is a common and serious complication in patients with decompensated cirrhosis. Precise quantification of bacterial DNA (bactDNA) and the related inflammatory response might add further information on the course of disease. The aim of the study was to evaluate the association between bactDNA, cytokine levels and clinical outcome.</p></div><div><h3>Methods</h3><p>Ascites and serum samples of 98 patients with decompensated liver cirrhosis (42 with SBP and 56 without SBP) as well as serum samples of 21 healthy controls were collected. BactDNA in ascites and serum was detected and quantified by 16S rRNA PCR. Concentrations of IL-1β, TNF-α, IL-6, IL-8 and IL-10 were measured by a LEGENDplexTM multi-analyte flow assay. Clinical data were collected and analyzed retrospectively.</p></div><div><h3>Results</h3><p>BactDNA was detected more frequently in ascites of patients with SBP (<em>n</em> = 24/42; 57.1%) than in ascites of patients without SBP (<em>n</em> = 5/56; 8.9%; <em>P</em> &lt; 0.001). Additionally, IL-6 levels in both ascites and serum were significantly higher in patients with SBP (ascites <em>P</em> &lt; 0.001, serum <em>P</em> = 0.036). The quantity of bactDNA in ascites was strongly correlated with polymorphonuclear neutrophil count in ascites (r = 0.755; <em>P</em> &lt; 0.001) as well as ascites IL-6 levels (r = 0.399; <em>P</em> &lt; 0.001). Receiver operating characteristic (ROC) curve analysis to diagnose SBP provided an AUC of 0.764 (95% CI: 0.661–0.867) for serum IL-6 levels, an AUC of 0.810 (95% CI: 0.714–0.905) for ascites IL-6 levels, and an AUC of 0.755 (95% CI: 0.651–0.858) for bactDNA levels in ascites.</p></div><div><h3>Conclusions</h3><p>The correlation between the amount of bactDNA and IL-6 confirms the pathophysiological relevance of bactDNA and IL-6 as potential biomarkers for the diagnosis of SBP.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0973688324000914/pdfft?md5=b56e4ea49bbff0715fcb1525c05005f8&pid=1-s2.0-S0973688324000914-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141026800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Issue Highlights 发行亮点
IF 3 Q2 Medicine Pub Date : 2024-05-01 DOI: 10.1016/S0973-6883(24)00099-9
{"title":"Issue Highlights","authors":"","doi":"10.1016/S0973-6883(24)00099-9","DOIUrl":"https://doi.org/10.1016/S0973-6883(24)00099-9","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140947582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Health-related Quality of Life in Patients With Liver Cirrhosis: A Randomized Study 肝硬化患者的健康相关生活质量:随机研究
IF 3 Q2 Medicine Pub Date : 2024-04-30 DOI: 10.1016/j.jceh.2024.101433
Siddheesh Rajpurohit, Balaji Musunuri, Pooja B. Mohan, Ganesh Bhat, Shiran Shetty

Background/Aims

Health-related quality of life (HRQoL) relates to how people perceive illness and treatment affects their physical health, emotional health, functional status, and social position. Along with clinical goals, HRQoL is significant. Therefore, the present study evaluates the effect of patient counseling and education on HRQoL of cirrhotic patients.

Methods

This prospective study was conducted in a tertiary care center of coastal Karnataka, Kasturba Medical College, Manipal, Karnataka from October 2022 with a three-month follow-up. Patients with a confirmed diagnosis of liver cirrhosis visiting the outpatient department of age ≥18 were enrolled in the study and divided on the basis of compensated and decompensated cirrhosis. Patients were randomized into two groups i.e., case and control in compensated and decompensated group through the envelop method of randomization. The case group received patient education and counseling along with standard medical therapy. CLDQ was used to evaluate HRQoL scores on baseline and after the third month.

Results

A total of 104 patients were enrolled with a mean age of 53.49 ± 11.25, with most being male (80.7%). Out of 104, 60 and 44 had compensated and decompensated cirrhosis. Case and control groups did not differ significantly on baseline. However, on follow-up, the compensated group showed significant improvement in abdominal symptoms, fatigue, and emotional functions. Meanwhile, the decompensated group showed significant improvement in activity, emotional function, and worry domain of CLDQ. Higher MELD scores were the significant factor associated with lower HRQoL scores.

Conclusion

Patient education and counseling positively impacted the fatigue, emotional, and worry domain of the CLDQ. Hence, the present study recommends making an effort to promote patient counseling and education via leaflets or videos.

背景/目的健康相关生活质量(HRQoL)与人们如何看待疾病和治疗对其身体健康、情绪健康、功能状态和社会地位的影响有关。随着临床目标的实现,HRQoL 具有重要意义。因此,本研究评估了患者咨询和教育对肝硬化患者 HRQoL 的影响。方法这项前瞻性研究于 2022 年 10 月在卡纳塔克邦马尼帕尔的卡斯特尔巴医学院沿海卡纳塔克邦的一家三级医疗中心进行,随访三个月。在门诊部就诊的肝硬化确诊患者中,年龄≥18 岁的患者被纳入研究,并按肝硬化代偿期和失代偿期进行划分。通过包络随机法将患者随机分为两组,即代偿组和失代偿组中的病例组和对照组。病例组在接受标准药物治疗的同时,还接受患者教育和咨询。结果 共有 104 名患者入组,平均年龄为(53.49±11.25)岁,大部分为男性(80.7%)。104 名患者中,60 人患有代偿期肝硬化,44 人患有失代偿期肝硬化。病例组和对照组在基线上没有明显差异。但在随访中,代偿组的腹部症状、疲劳和情绪功能有明显改善。与此同时,失代偿组在活动、情绪功能和CLDQ的担忧领域有明显改善。较高的 MELD 评分是与较低的 HRQoL 评分相关的重要因素。因此,本研究建议通过传单或视频努力促进患者咨询和教育。
{"title":"Health-related Quality of Life in Patients With Liver Cirrhosis: A Randomized Study","authors":"Siddheesh Rajpurohit,&nbsp;Balaji Musunuri,&nbsp;Pooja B. Mohan,&nbsp;Ganesh Bhat,&nbsp;Shiran Shetty","doi":"10.1016/j.jceh.2024.101433","DOIUrl":"https://doi.org/10.1016/j.jceh.2024.101433","url":null,"abstract":"<div><h3>Background/Aims</h3><p>Health-related quality of life (HRQoL) relates to how people perceive illness and treatment affects their physical health, emotional health, functional status, and social position. Along with clinical goals, HRQoL is significant. Therefore, the present study evaluates the effect of patient counseling and education on HRQoL of cirrhotic patients.</p></div><div><h3>Methods</h3><p>This prospective study was conducted in a tertiary care center of coastal Karnataka, Kasturba Medical College, Manipal, Karnataka from October 2022 with a three-month follow-up. Patients with a confirmed diagnosis of liver cirrhosis visiting the outpatient department of age ≥18 were enrolled in the study and divided on the basis of compensated and decompensated cirrhosis. Patients were randomized into two groups i.e., case and control in compensated and decompensated group through the envelop method of randomization. The case group received patient education and counseling along with standard medical therapy. CLDQ was used to evaluate HRQoL scores on baseline and after the third month.</p></div><div><h3>Results</h3><p>A total of 104 patients were enrolled with a mean age of 53.49 ± 11.25, with most being male (80.7%). Out of 104, 60 and 44 had compensated and decompensated cirrhosis. Case and control groups did not differ significantly on baseline. However, on follow-up, the compensated group showed significant improvement in abdominal symptoms, fatigue, and emotional functions. Meanwhile, the decompensated group showed significant improvement in activity, emotional function, and worry domain of CLDQ. Higher MELD scores were the significant factor associated with lower HRQoL scores.</p></div><div><h3>Conclusion</h3><p>Patient education and counseling positively impacted the fatigue, emotional, and worry domain of the CLDQ. Hence, the present study recommends making an effort to promote patient counseling and education via leaflets or videos.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141241797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Partial Splenic Artery Embolization for the Management of Symptomatic Hypersplenism in Portal Hypertension: Clinical Insights from a Case Series 部分脾动脉栓塞治疗门脉高压症症状性脾功能亢进:病例系列的临床启示
IF 3 Q2 Medicine Pub Date : 2024-04-29 DOI: 10.1016/j.jceh.2024.101435
Mayur Satai, Arun Vaidya, Krantikumar Rathod, Ankita Singh, Sidharth Harindranath, Biswa R. Patra, Akash Shukla

Background and aims

Partial splenic artery embolization (PSAE) is an alternative treatment modality for managing hypersplenism secondary to portal hypertension. We are presenting a case series of patients with portal hypertension who underwent PSAE for symptomatic hypersplenism.

Methods

We included patients with portal hypertension who underwent PSAE from January 2022 to December 2022. Patients' characteristics and procedure related complications were noted. Data were analyzed for improvement in the hematological parameters.

Results

A total of 11 (7 women, median age 34 [18–56] years) patients were included. Three patients were cirrhotic (hepatitis B-2, metabolic dysfunction–associated steatotic liver disease −1) and 8 were non-cirrhotic (extra-hepatic portal vein obstruction-5, Non cirrhotic portal fibrosis-3). Splenic artery aneurysm was concomitantly present in 5 cases. Technical success was achieved in all cases. Post embolization, hemoglobin, white blood cells and platelet counts improved at 4 weeks, 12 weeks and 24 weeks along with symptomatic improvement. All patients had post-embolization syndrome. One patient developed transient ascites and secondary bacterial peritonitis which was managed conservatively. One patient died due to splenic abscess and septicemia.

Conclusion

Although, hematological parameters and symptoms improve post procedure, PSAE is associated with major complications and should be performed judiciously in selected cases only. Graphical abstract is presented in Figure 1.

背景和目的部分脾动脉栓塞术(PSAE)是治疗继发于门脉高压症的脾功能亢进的一种替代治疗方式。我们将对因症状性脾功能亢进而接受部分脾动脉栓塞术的门静脉高压症患者进行病例系列研究。方法我们纳入了 2022 年 1 月至 2022 年 12 月期间接受部分脾动脉栓塞术的门静脉高压症患者。我们记录了患者的特征和手术相关并发症。结果共纳入 11 名患者(7 名女性,中位年龄 34 [18-56] 岁)。其中 3 例为肝硬化患者(乙型肝炎-2 例,代谢功能障碍相关性脂肪肝-1 例),8 例为非肝硬化患者(肝外门静脉阻塞-5 例,非肝硬化门脉纤维化-3 例)。5例同时存在脾动脉瘤。所有病例都取得了技术成功。栓塞术后,血红蛋白、白细胞和血小板计数在 4 周、12 周和 24 周时均有所改善,症状也有所改善。所有患者都出现了栓塞后综合征。一名患者出现一过性腹水和继发性细菌性腹膜炎,经保守治疗后好转。结论虽然血液学参数和症状在术后均有所改善,但 PSAE 与重大并发症有关,应仅在选定的病例中谨慎实施。图 1 展示了图解摘要。
{"title":"Partial Splenic Artery Embolization for the Management of Symptomatic Hypersplenism in Portal Hypertension: Clinical Insights from a Case Series","authors":"Mayur Satai,&nbsp;Arun Vaidya,&nbsp;Krantikumar Rathod,&nbsp;Ankita Singh,&nbsp;Sidharth Harindranath,&nbsp;Biswa R. Patra,&nbsp;Akash Shukla","doi":"10.1016/j.jceh.2024.101435","DOIUrl":"https://doi.org/10.1016/j.jceh.2024.101435","url":null,"abstract":"<div><h3>Background and aims</h3><p>Partial splenic artery embolization (PSAE) is an alternative treatment modality for managing hypersplenism secondary to portal hypertension. We are presenting a case series of patients with portal hypertension who underwent PSAE for symptomatic hypersplenism.</p></div><div><h3>Methods</h3><p>We included patients with portal hypertension who underwent PSAE from January 2022 to December 2022. Patients' characteristics and procedure related complications were noted. Data were analyzed for improvement in the hematological parameters.</p></div><div><h3>Results</h3><p>A total of 11 (7 women, median age 34 [18–56] years) patients were included. Three patients were cirrhotic (hepatitis B-2, metabolic dysfunction–associated steatotic liver disease −1) and 8 were non-cirrhotic (extra-hepatic portal vein obstruction-5, Non cirrhotic portal fibrosis-3). Splenic artery aneurysm was concomitantly present in 5 cases. Technical success was achieved in all cases. Post embolization, hemoglobin, white blood cells and platelet counts improved at 4 weeks, 12 weeks and 24 weeks along with symptomatic improvement. All patients had post-embolization syndrome. One patient developed transient ascites and secondary bacterial peritonitis which was managed conservatively. One patient died due to splenic abscess and septicemia.</p></div><div><h3>Conclusion</h3><p>Although, hematological parameters and symptoms improve post procedure, PSAE is associated with major complications and should be performed judiciously in selected cases only. Graphical abstract is presented in Figure 1.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141097840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Endoscopic Ultrasound Guided Radiofrequency Ablation for Caudate Lobe Hepatocellular Carcinoma: A New Paradigm in Endohepatology 内窥镜超声引导下的尾状叶肝细胞癌射频消融术:内科肝病学的新范例
IF 3 Q2 Medicine Pub Date : 2024-04-26 DOI: 10.1016/j.jceh.2024.101438
Arka De , Yogendra Kumar , Arpit Shastri , Chandragiri P. Ganesh , Arwinder Singh , Sahaj Rathi , Sreedhara B. Chaluvashetty , Ajay Duseja

Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a promising technique for treating small left hepatic lesions, particularly where ablation via percutaneous route is deemed to be technically difficult. Herein, we report a case of a 64-year-old cirrhotic patient with caudate lobe hepatocellular carcinoma (HCC) who underwent EUS-RFA, resulting in complete ablation of the tumor and also review the related literature.

内镜超声引导下射频消融术(EUS-RFA)是治疗左肝小病灶的一种很有前景的技术,尤其是在经皮途径消融被认为存在技术难度的情况下。在此,我们报告了一例 64 岁的肝硬化尾状叶肝细胞癌(HCC)患者接受 EUS-RFA 治疗并完全消融肿瘤的病例,并回顾了相关文献。
{"title":"Endoscopic Ultrasound Guided Radiofrequency Ablation for Caudate Lobe Hepatocellular Carcinoma: A New Paradigm in Endohepatology","authors":"Arka De ,&nbsp;Yogendra Kumar ,&nbsp;Arpit Shastri ,&nbsp;Chandragiri P. Ganesh ,&nbsp;Arwinder Singh ,&nbsp;Sahaj Rathi ,&nbsp;Sreedhara B. Chaluvashetty ,&nbsp;Ajay Duseja","doi":"10.1016/j.jceh.2024.101438","DOIUrl":"https://doi.org/10.1016/j.jceh.2024.101438","url":null,"abstract":"<div><p>Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a promising technique for treating small left hepatic lesions, particularly where ablation via percutaneous route is deemed to be technically difficult. Herein, we report a case of a 64-year-old cirrhotic patient with caudate lobe hepatocellular carcinoma (HCC) who underwent EUS-RFA, resulting in complete ablation of the tumor and also review the related literature.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140948448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Portal Vein Reconstruction-trans Jugular Intrahepatic Portosystemic Shunt and Portal Vein Stenting in Patients With Extrahepatic Portal Vein Obstruction 肝外门静脉阻塞患者的门静脉重建--经颈静脉肝内门体分流术和门静脉支架植入术
IF 3 Q2 Medicine Pub Date : 2024-04-25 DOI: 10.1016/j.jceh.2024.101437
Sayan Malakar , Rajanikant R. Yadav , Gaurav Pandey , Praveer Rai , Gurubasava Sajjan , Anurag Mehndiratta , Malla V.A. Gangadhar Rao , S. Rakesh Kumar , Dhruv Thakur , Pritam Das , Samir Mohindra , Supriya Sharma

Extrahepatic portal vein thrombosis (EHPVO) is an uncommon cause of portal hypertension. In the long term, patients may develop portal cavernoma cholangiopathy (PCC). Up to 30%–40% of patients with EHPVO may not have shuntable veins and are often difficult to manage surgically. Interventional treatment including portal vein recanalisation-trans jugular intrahepatic portosystemic shunt (PVRecan-TIPS) has been used for patients with EHPVO. However, PV reconstruction-trans jugular intrahepatic portosystemic shunt (PVRecon-TIPS) and portal vein stenting are novel techniques for managing such patients with EHPVO with non-shuntable venous anatomy. In contrast to PVRecan-TIPS, PV reconstruction-TIPS (PVRecon-TIPS) is performed through intrahepatic collaterals. Here we present six cases of PCC who presented with recurrent acute variceal bleeding (AVB) and or refractory biliary stricture. They did not have any shuntable veins. PVRecon-TIPS was performed for five patients whilst PV stenting was done in one. Amongst the six patients, one died of sepsis whilst one who developed hyponatremia and hepatic encephalopathy was salvaged with conservative management. Following the procedure, they were started on anti-coagulation. Decompression of cavernoma was documented in all other patients. Biliary changes improved completely in 40% of patients.

肝外门静脉血栓(EHPVO)是门静脉高压症的一种不常见病因。长此以往,患者可能会发展成门静脉海绵状胆管病(PCC)。多达 30%-40% 的 EHPVO 患者可能没有可分流的静脉,通常难以通过手术治疗。介入治疗包括门静脉再通-经颈静脉肝内门体分流术(PVRecan-TIPS),已被用于治疗 EHPVO 患者。然而,PV 重建--经颈静脉肝内门体分流术(PVRecon-TIPS)和门静脉支架植入术是治疗此类静脉解剖结构不可分流的 EHPVO 患者的新技术。与PVRecan-TIPS不同,PV重建-TIPS(PVRecon-TIPS)是通过肝内袢进行的。在此,我们介绍了六例 PCC 病例,他们都出现了复发性急性静脉曲张出血(AVB)和或难治性胆道狭窄。他们没有任何可分流的静脉。五名患者接受了 PVRecon-TIPS 手术,一名患者接受了 PV 支架植入术。六名患者中,一名死于败血症,一名出现低钠血症和肝性脑病,经保守治疗后获救。手术后,他们开始接受抗凝治疗。所有其他患者的海绵体瘤均有减压记录。40%的患者胆道病变完全好转。
{"title":"Portal Vein Reconstruction-trans Jugular Intrahepatic Portosystemic Shunt and Portal Vein Stenting in Patients With Extrahepatic Portal Vein Obstruction","authors":"Sayan Malakar ,&nbsp;Rajanikant R. Yadav ,&nbsp;Gaurav Pandey ,&nbsp;Praveer Rai ,&nbsp;Gurubasava Sajjan ,&nbsp;Anurag Mehndiratta ,&nbsp;Malla V.A. Gangadhar Rao ,&nbsp;S. Rakesh Kumar ,&nbsp;Dhruv Thakur ,&nbsp;Pritam Das ,&nbsp;Samir Mohindra ,&nbsp;Supriya Sharma","doi":"10.1016/j.jceh.2024.101437","DOIUrl":"10.1016/j.jceh.2024.101437","url":null,"abstract":"<div><p>Extrahepatic portal vein thrombosis (EHPVO) is an uncommon cause of portal hypertension. In the long term, patients may develop portal cavernoma cholangiopathy (PCC). Up to 30%–40% of patients with EHPVO may not have shuntable veins and are often difficult to manage surgically. Interventional treatment including portal vein recanalisation-trans jugular intrahepatic portosystemic shunt (PVRecan-TIPS) has been used for patients with EHPVO. However, PV reconstruction-trans jugular intrahepatic portosystemic shunt (PVRecon-TIPS) and portal vein stenting are novel techniques for managing such patients with EHPVO with non-shuntable venous anatomy. In contrast to PVRecan-TIPS, PV reconstruction-TIPS (PVRecon-TIPS) is performed through intrahepatic collaterals. Here we present six cases of PCC who presented with recurrent acute variceal bleeding (AVB) and or refractory biliary stricture. They did not have any shuntable veins. PVRecon-TIPS was performed for five patients whilst PV stenting was done in one. Amongst the six patients, one died of sepsis whilst one who developed hyponatremia and hepatic encephalopathy was salvaged with conservative management. Following the procedure, they were started on anti-coagulation. Decompression of cavernoma was documented in all other patients. Biliary changes improved completely in 40% of patients.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140767787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dental and ENT Evaluation Before Liver Transplantation "肝移植前的牙科和内科评估"
IF 3 Q2 Medicine Pub Date : 2024-04-18 DOI: 10.1016/j.jceh.2024.101431
Rakesh K. Jagdish , Preetam Chappity , S. Lata

The assessment of dental and ear, nose and throat (ENT) conditions holds significant importance in the pre-transplantation evaluation for individuals undergoing liver transplantation. This evaluation aims to address concerns related to dental and ENT issues both before and after liver transplantation. These concerns include the risk of sepsis, the impact of post-transplantation immunosuppression, the detection of existing malignancies, including oral potentially malignant disorders (OPMDs), and identifying any contraindications to the transplantation procedure. However, it is worth noting that there exists a notable absence of clear guidelines and protocols in the existing literature regarding this practice. Moreover, recent studies have presented conflicting results, and concerns have arisen regarding the cost-effectiveness of these evaluations. It is crucial to perform these investigations judiciously to avoid unnecessary testing burdens and delays in placing patients on waiting lists, particularly when considering live donor liver transplantation (LDLT) evaluations. A comprehensive examination of the oral and ENT regions, in conjunction with relevant laboratory tests, can play a pivotal role in identifying and managing oral and ENT diseases before the liver transplantation procedure. Timely recognition and treatment of potential issues are essential for minimizing perioperative morbidity and mortality. There is an evident need for prospective trials and studies to further explore and establish guidelines in the critical area of dental and ENT evaluation in liver transplantation recipients. Such research efforts would contribute significantly to enhancing our understanding and management of oral and ENT conditions in the pre-transplantation setting, ultimately improving patient care and outcomes.

在对接受肝脏移植的患者进行移植前评估时,牙科和耳鼻喉科(ENT)状况的评估非常重要。该评估旨在解决肝脏移植前后与牙科和耳鼻喉科相关的问题。这些问题包括败血症的风险、移植后免疫抑制的影响、现有恶性肿瘤(包括口腔潜在恶性疾病)的检测,以及确定移植手术的禁忌症。然而,值得注意的是,现有文献中明显缺乏有关这一做法的明确指南和协议。此外,近期的研究结果相互矛盾,人们对这些评估的成本效益也产生了担忧。明智地进行这些检查以避免不必要的检查负担和延误将患者列入候诊名单至关重要,尤其是在考虑进行活体肝移植(LDLT)评估时。对口腔和耳鼻喉区域进行全面检查,并结合相关实验室检测,可在肝脏移植手术前发现和控制口腔和耳鼻喉疾病方面发挥关键作用。及时发现和治疗潜在的问题对于最大限度地降低围手术期的发病率和死亡率至关重要。在肝移植受者的口腔和耳鼻喉科评估这一关键领域,显然需要进行前瞻性试验和研究,以进一步探索和制定指导方针。这些研究工作将极大地促进我们对移植前口腔和耳鼻喉科疾病的理解和管理,最终改善患者护理和治疗效果。
{"title":"Dental and ENT Evaluation Before Liver Transplantation","authors":"Rakesh K. Jagdish ,&nbsp;Preetam Chappity ,&nbsp;S. Lata","doi":"10.1016/j.jceh.2024.101431","DOIUrl":"10.1016/j.jceh.2024.101431","url":null,"abstract":"<div><p>The assessment of dental and ear, nose and throat (ENT) conditions holds significant importance in the pre-transplantation evaluation for individuals undergoing liver transplantation. This evaluation aims to address concerns related to dental and ENT issues both before and after liver transplantation. These concerns include the risk of sepsis, the impact of post-transplantation immunosuppression, the detection of existing malignancies, including oral potentially malignant disorders (OPMDs), and identifying any contraindications to the transplantation procedure. However, it is worth noting that there exists a notable absence of clear guidelines and protocols in the existing literature regarding this practice. Moreover, recent studies have presented conflicting results, and concerns have arisen regarding the cost-effectiveness of these evaluations. It is crucial to perform these investigations judiciously to avoid unnecessary testing burdens and delays in placing patients on waiting lists, particularly when considering live donor liver transplantation (LDLT) evaluations. A comprehensive examination of the oral and ENT regions, in conjunction with relevant laboratory tests, can play a pivotal role in identifying and managing oral and ENT diseases before the liver transplantation procedure. Timely recognition and treatment of potential issues are essential for minimizing perioperative morbidity and mortality. There is an evident need for prospective trials and studies to further explore and establish guidelines in the critical area of dental and ENT evaluation in liver transplantation recipients. Such research efforts would contribute significantly to enhancing our understanding and management of oral and ENT conditions in the pre-transplantation setting, ultimately improving patient care and outcomes.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140756412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Case of First-line Atezolizumab Plus Bevacizumab Use in Recurrence of Combined Hepatocellular Cholangiocarcinoma After Surgical Resection 手术切除后合并肝细胞胆管癌复发时一线使用阿特珠单抗和贝伐单抗的病例
IF 3 Q2 Medicine Pub Date : 2024-04-16 DOI: 10.1016/j.jceh.2024.101430
Gordon T. Moffat, Kai Duan, Jennifer J. Knox
{"title":"A Case of First-line Atezolizumab Plus Bevacizumab Use in Recurrence of Combined Hepatocellular Cholangiocarcinoma After Surgical Resection","authors":"Gordon T. Moffat,&nbsp;Kai Duan,&nbsp;Jennifer J. Knox","doi":"10.1016/j.jceh.2024.101430","DOIUrl":"10.1016/j.jceh.2024.101430","url":null,"abstract":"","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140797360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alterations in CD4+ T-cell Subsets in Living Donor Liver Transplantation Associated With Graft Rejection 活体肝移植后 CD4+ T 细胞亚群的变化可预测移植物排斥反应
IF 3 Q2 Medicine Pub Date : 2024-04-16 DOI: 10.1016/j.jceh.2024.101428
Ankur Vagadiya , Rashi Sehgal , Nirupma Trehanpati , Viniyendra Pamecha

Background and objectives

Regulatory T-cells (Tregs) play a key role in immune homeostasis after organ transplantation. However, the role of CD4+ T cell subsets in early acute rejection is still not well understood. Therefore, our aim was to determine changes in CD4+ T-cell subsets in living donor liver transplantation (LDLT).

Methods

LDLT patients were assessed for T-cell subsets, Tregs frequencies and their functionality by flow-cytometry at peri- and post-transplant in the span of 1 year.

Results

33 patients were followed up and 11 (33%) patients have developed early acute cellular rejection (ACR). At peri-transplant time point, MFI of Foxp3+ Tregs was significantly increased compared to HC (P = 0.04). However, CD4+CD25+Foxp3+/CD127 Tregs numbers and IL-10, IL-17 and TGF-β secreting functional Tregs were significantly decreased at 3 months compared to peri-transplant (P = 0.003). But in patients with rejection, CD4+CD25+FOXP3+ and CD4+CD25+CD127 Tregs were significantly decreased at day 3 compared to no rejection group (P = 0.048). Patients with rejection also showed significantly decreased numbers of IL-17 and TGF-β secreting CD4+CD25+FOXP3+ Tregs at peri-transplant time (P = 0.04, P = 0.03) compared to no rejection. Further, rejection group showed decreased terminally differentiated effector memory (TEMRA) at peri-transplant and day 7 (P = 0.048 and P = 0.01). Additionally, CD4+ central memory (CM) was decreased at peri-transplant (P = 0.05), 1 month (P = 0.04), and 3 to 6 month (P = 0.02).

Interpretation and conclusion

Tregs frequencies were significantly decreased in peri-TX in rejection patients. Further, decreased frequencies of CD4+ TEMRA and CD4+ CM at day 7 and 1 month were associated with rejection.

背景和目的调节性 T 细胞(Tregs)在器官移植后的免疫平衡中发挥着关键作用。然而,CD4+ T细胞亚群在早期急性排斥反应中的作用仍不十分清楚。因此,我们的目的是确定活体肝移植(LDLT)中 CD4+ T 细胞亚群的变化。结果 33 例患者接受了随访,其中 11 例(33%)患者出现了早期急性细胞排斥反应(ACR)。在移植周围时间点,Foxp3+ Tregs 的 MFI 比 HC 显著增加(P = 0.04)。然而,CD4+CD25+Foxp3+/CD127- Tregs数量以及分泌IL-10、IL-17和TGF-β的功能性Tregs数量在3个月时比移植前明显减少(P = 0.003)。但与无排斥反应组相比,排斥反应患者的 CD4+CD25+FOXP3+ 和 CD4+CD25+CD127- Tregs 在第 3 天明显减少(P = 0.048)。与无排斥反应组相比,排斥反应患者在移植前后分泌 IL-17 和 TGF-β 的 CD4+CD25+FOXP3+ Tregs 数量也明显减少(P = 0.04,P = 0.03)。此外,排斥反应组在移植前后和第7天显示终末分化效应记忆(TEMRA)减少(P = 0.048 和 P = 0.01)。此外,CD4+中央记忆(CM)在移植周(P = 0.05)、1 个月(P = 0.04)和 3 至 6 个月(P = 0.02)时均有所下降。此外,第 7 天和 1 个月时 CD4+ TEMRA 和 CD4+ CM 的频率降低与排斥反应有关。
{"title":"Alterations in CD4+ T-cell Subsets in Living Donor Liver Transplantation Associated With Graft Rejection","authors":"Ankur Vagadiya ,&nbsp;Rashi Sehgal ,&nbsp;Nirupma Trehanpati ,&nbsp;Viniyendra Pamecha","doi":"10.1016/j.jceh.2024.101428","DOIUrl":"10.1016/j.jceh.2024.101428","url":null,"abstract":"<div><h3>Background and objectives</h3><p>Regulatory T-cells (Tregs) play a key role in immune homeostasis after organ transplantation. However, the role of CD4<sup>+</sup> T cell subsets in early acute rejection is still not well understood. Therefore, our aim was to determine changes in CD4<sup>+</sup> T-cell subsets in living donor liver transplantation (LDLT).</p></div><div><h3>Methods</h3><p>LDLT patients were assessed for T-cell subsets, Tregs frequencies and their functionality by flow-cytometry at peri- and post-transplant in the span of 1 year.</p></div><div><h3>Results</h3><p>33 patients were followed up and 11 (33%) patients have developed early acute cellular rejection (ACR). At peri-transplant time point, MFI of Foxp3<sup>+</sup> Tregs was significantly increased compared to HC (<em>P</em> = 0.04). However, CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>/CD127<sup>–</sup> Tregs numbers and IL-10, IL-17 and TGF-β secreting functional Tregs were significantly decreased at 3 months compared to peri-transplant (<em>P</em> = 0.003). But in patients with rejection, CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> and CD4<sup>+</sup>CD25<sup>+</sup>CD127<sup>−</sup> Tregs were significantly decreased at day 3 compared to no rejection group (<em>P</em> = 0.048). Patients with rejection also showed significantly decreased numbers of IL-17 and TGF-β secreting CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> Tregs at peri-transplant time (<em>P</em> = 0.04, <em>P</em> = 0.03) compared to no rejection. Further, rejection group showed decreased terminally differentiated effector memory (TEMRA) at peri-transplant and day 7 (<em>P</em> = 0.048 and <em>P</em> = 0.01). Additionally, CD4<sup>+</sup> central memory (CM) was decreased at peri-transplant (<em>P</em> = 0.05), 1 month (<em>P</em> = 0.04), and 3 to 6 month (<em>P</em> = 0.02).</p></div><div><h3>Interpretation and conclusion</h3><p>Tregs frequencies were significantly decreased in peri-TX in rejection patients. Further, decreased frequencies of CD4<sup>+</sup> TEMRA and CD4<sup>+</sup> CM at day 7 and 1 month were associated with rejection.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140777726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case of Ectopic Variceal Bleed Managed With Percutaneous Transhepatic Portal Vein Recanalization 经皮肝门静脉再通术治疗异位静脉曲张出血病例
IF 3 Q2 Medicine Pub Date : 2024-04-16 DOI: 10.1016/j.jceh.2024.101429
Tara P. Tripathy , Ranjan K. Patel , Aryamon Mukherjee , Brahmadutta Pattanaik , Hemant K. Nayak , Sanjib Kar , Manas K. Panigrahi

A variety of complications and associated clinical presentations may be seen in patients with cirrhotic and non-cirrhotic portal hypertension. We present one such case of Upper GI hemorrhage from ectopic duodenal varices in a case of pre-hepatic portal hypertension due to Extrahepatic Portal Venous Obstruction (EHPVO). The case was managed successfully with endovascular Portal Vein Recanalization (PVR) and metallic stent deployment. With adequate technical success, improved symptoms, and laboratory parameters, the patient was discharged on long-term anticoagulation and interval follow-up.

肝硬化和非肝硬化门静脉高压症患者可能会出现各种并发症和相关临床表现。我们介绍了一例因肝外门静脉阻塞(EHPVO)引起的肝前门静脉高压症患者因十二指肠静脉曲张异位而导致上消化道大出血的病例。该病例经血管内门静脉再通术(PVR)和金属支架置入术后处理成功。由于技术充分成功、症状和实验室指标得到改善,患者出院后接受了长期抗凝治疗和间隔随访。
{"title":"Case of Ectopic Variceal Bleed Managed With Percutaneous Transhepatic Portal Vein Recanalization","authors":"Tara P. Tripathy ,&nbsp;Ranjan K. Patel ,&nbsp;Aryamon Mukherjee ,&nbsp;Brahmadutta Pattanaik ,&nbsp;Hemant K. Nayak ,&nbsp;Sanjib Kar ,&nbsp;Manas K. Panigrahi","doi":"10.1016/j.jceh.2024.101429","DOIUrl":"10.1016/j.jceh.2024.101429","url":null,"abstract":"<div><p>A variety of complications and associated clinical presentations may be seen in patients with cirrhotic and non-cirrhotic portal hypertension. We present one such case of Upper GI hemorrhage from ectopic duodenal varices in a case of pre-hepatic portal hypertension due to Extrahepatic Portal Venous Obstruction (EHPVO). The case was managed successfully with endovascular Portal Vein Recanalization (PVR) and metallic stent deployment. With adequate technical success, improved symptoms, and laboratory parameters, the patient was discharged on long-term anticoagulation and interval follow-up.</p></div>","PeriodicalId":15479,"journal":{"name":"Journal of Clinical and Experimental Hepatology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical and Experimental Hepatology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1